Clovis Oncology (NASDAQ:CLVS) Downgraded by BidaskClub to Strong Sell

0
47

Clovis Oncology stock has undergone multiple analysts rating changes in the recent past.  Clovis Oncology Downgraded by BidaskClub on 7/3/2020. In a note to investors, the firm issued a new rating of Strong Sell. The analysts previously had rating of Sell.

Shares of Clovis Oncology traded down -$0.08 on Thursday, reaching $6.61. 3365804 shares of the stock traded hands, compared to its average volume of 5828047. Shares of Clovis Oncology closed trading at $6.61 on Thursday. The firm’s 50 day moving average is $7.61 and its 200 day moving average is $7.46.Clovis Oncology  has a 12 month low of $6.49 and a 12 month high of $17.37. While on yearly highs and lows, Clovis Oncology’s today has traded high as $6.84 and has touched $6.49 on the downward trend. See More Analyst Rating at: RATING

Clovis Oncology Earnings and What to expect: 

Clovis Oncology last posted its quarterly earnings data on May 5th, 2020. The biopharmaceutical company reported ($1.28) EPS for the quarter, hitting analysts’ consensus estimates of ($1.28). The company earned $42.56 million during the quarter, compared to the consensus estimate of $41.80 million. Clovis Oncology has generated ($7.60) earnings per share over the last year. Clovis Oncology has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, August 6th, 2020 based off prior year’s report dates.

Earnings for Clovis Oncology are expected to grow in the coming year, from ($4.22) to ($2.59) per share. The P/E ratio of Clovis Oncology is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Clovis Oncology is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Latest Insiders Trading and Volume : 

  • Insider Ownership Percentage: 8.30%
  • On 6/22/2020 Insider Lindsey Rolfe Sell 1,728 at average share price of $6.74 which equates to $11,646.72 in money value.
  • On 6/3/2020 Insider Gillian C Ivers-Read Sell 598 at average price of  $7.03 with total value of : Not Data Available
  • On 5/27/2020 Insider Daniel W Muehl Sell 247 at average price of  $6.91 with total value of : $1,706.77

Analyst at BidaskClub are also talking about :

  • 7/3/2020 – Yunji was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating. (View)
  • 7/3/2020 – Yintech Investment was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating. (View)
  • 7/3/2020 – 111 was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating. (View)
  • 7/3/2020 – Intersect ENT was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating. (View)

Clovis Oncology (NASDAQ:CLVS) Moving Average Technical Analysis

5 day Moving Average is $6.82 And 5 day price change is -$0.70 (-9.58%)  with average volume for 5 day average is 5,008,020. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $7.04 and 20 day price change is $0.13 (2.01%) and average 20 day moving volume is 4,782,840. 50 day moving average is $7.61  and 50 day price change is -$2.56 ( -27.92%)  and with average volume for 50 days is : 7,209,340. 200 day moving average is $7.46  and 200 day price change is $1.27 (23.78%)  and with average volume for 200 days is : 7,984,178.

See More Analyst Rating at: RATING